Australian Drug Discovery Company ‘Phylogica’ Forms Alliance with German Biotechnology Company ‘XLprotein GmbH’
Canberra, Australia (News4us.com) February 01, 2011
Australian drug discovery company, Phylogica Limited has formed an alliance with a German company, which could prolong the therapeutic life of anti-inflammatory drugs—and improve treatment for rheumatoid arthritis, coronary artery disease and inflammatory bowel disease.
The German biotechnology company, XLprotein GmbH, specialises in extending the circulation half-life of biopharmaceutical drugs by fusing the drug in a special polymer of amino acids, thereby slowing the clearance of the drug from the body.
Through the alliance, Phylogica (ASX:PYC) will gain access to XLprotein’s technology, allowing it to strengthen its Phylomer drug discovery platform. Phylomer drug prototypes are a special kind of peptide that belongs to a class of drugs called Biologics or ‘smart’ drugs.
XL protein’s PASylation technology uses genetic-based techniques to fuse a polymer of natural amino acids onto the relevant peptide or protein-based drug, which slows the body’s clearance of the drug and prolongs the therapeutic effect.
It is anticipated that the plasma half-life of PASylated Phylomers will be significantly extended, meaning less frequent administration and a lower dose.
Phylogica’s Chief Executive Officer, Dr Paul Watt, said the alliance could lead to several benefits for consumers. “This deal provides us with access to the next generation of polypeptide fusions for optimising the half-life of our Phylomers,” he said.
“The technology combination of XL-protein and Phylogica could also significantly facilitate the ease of manufacturing and lower the cost of goods.”
Dr Arne Skerra, founder and CEO of XL-protein GmbH, said, “XL-protein is delighted to apply its PASylation technology to Phylomers, which will validate the benefit of this revolutionary half-life extension technology to a highly promising class of therapeutic peptide drugs.”
Phylogica and XL-protein will initially collaborate on a pilot study to validate the technology in combination with one of Phylogica’s Phylomer peptides in its anti-inflammatory program.
Under the terms of the agreement, Phylogica has an option to obtain an exclusive license to the PASylation technology for peptide-based products in certain circumstances.
Click here for more information on opportunities for Australian biotech firms in Germany.
Short URL: http://www.news4us.com/?p=5760